Non-valvular atrial fibrillation (NVAF) is a prevalent cardiac arrhythmia characterized by irregular and often accelerated heartbeats. Distinguishing itself from valvular atrial fibrillation, which is linked to heart valve anomalies, NVAF manifests in the absence of significant valve issues. This cardiac condition heightens the susceptibility to the formation of blood clots in the atria, posing a potential risk of stroke. The management of NVAF typically revolves around the administration of anticoagulant medications to impede blood clot formation and regulate heart rate. Moreover, healthcare practitioners may explore rhythm control strategies aimed at reinstating a normal heart rhythm. Given that NVAF is frequently a persistent condition, a holistic approach that takes into account individual patient factors is indispensable for effective treatment and mitigating the risk of associated complications. Consistent monitoring and collaborative efforts between patients and healthcare professionals are integral elements in the comprehensive management of non-valvular atrial fibrillation.
Title : Novel ways of cardiovascular risk assessment
Syed Raza, Awali Hospital, Bahrain
Title : Preventing sports-related cardiac arrest: Coronary artery calcium scoring stratifies the benefit of low-dose aspirin use for risk reduction
Arthur J Siegel, Massachusetts General Hospital, United States
Title : Empathy and precision: Revolutionizing communication between cardiologists and patients
Iris Panagiota Efthymiou, University of Greenwich, United Kingdom
Title : Ex-situ organ perfusion and cardiac performance improvement
Y J H J Taverne, Erasmus University Medical Center, Netherlands
Title : Subclinical atherosclerosis: Association with additional risk factors and somatic diseases
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : The past, present and future of AI in cardiology
Narendra Kumar, HeartbeatsZ Academy, United Kingdom